Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 24 April 2019, 08:36 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected as Competitive ICT Strategy Company for 2019
Recognized for Taking on Challenge of Transformation to New Business Models by Integrating Management and Ict Strategies

TOKYO, Apr 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Competitive IT Strategy Company 2019 as a company that is engaged in the strategic utilization of IT. This marks the first time a pharmaceutical company has been selected as a Competitive IT Strategy Company.

The aim of the Competitive IT Strategy Company program is to introduce companies as attractive companies to investors who emphasize improving corporate value over the mid- to long-term and to promote companies? Competitive IT Strategies. Under the program, METI and TSE jointly select and announce companies who are engaged in the strategic use of IT.

Companies are assessed according to five areas: "Utilization of IT to increase corporate value in terms of management policies and plans," "Strategic utilization of IT to increase corporate value," "Systems and personnel for promoting the Competitive IT Strategy," "Fundamental initiatives supporting the Competitive IT Strategy," as well as "Initiatives focused on evaluating and improving IT investment to increase corporate value."

In this fifth iteration of the program, 29 companies were selected from among approximately 3,600 publicly-listed Japanese companies.

Under the ICT Driven Innovation strategy in the medium-term business plan EWAY2025, Eisai is promoting various initiatives using IT for the enhancement of corporate value in order to realize a digital transformation that integrates management and ICT strategies. Eisai?s recognition as a Competitive IT Strategy Company highlighted its utilization of IT to contribute to the enhancement of corporate value as well as its application of new digital technologies.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Based on this human health care (hhc) philosophy, Eisai will take this opportunity to continue employing competitive IT strategy to further improve productivity and create innovation, and strive to further enhance corporate value.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120 


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Apr 18, 2025 15:52 HKT/SGT
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 5, 2025 08:09 HKT/SGT
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 4, 2025 16:22 HKT/SGT
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 3, 2025 14:41 HKT/SGT
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
Mar 3, 2025 12:53 HKT/SGT
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
Feb 28, 2025 11:31 HKT/SGT
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: